Last reviewed · How we verify

mFOLFIRINOX-FOLFIRI intensified chemotherapy

Seoul National University Hospital · Phase 3 active Small molecule

mFOLFIRINOX-FOLFIRI intensified chemotherapy is a Combination chemotherapy regimen Small molecule drug developed by Seoul National University Hospital. It is currently in Phase 3 development for Metastatic colorectal cancer (phase 3 investigation).

mFOLFIRINOX-FOLFIRI is an intensified chemotherapy regimen combining fluorouracil, leucovorin, irinotecan, and oxaliplatin to inhibit DNA synthesis and induce apoptosis in cancer cells.

mFOLFIRINOX-FOLFIRI is an intensified chemotherapy regimen combining fluorouracil, leucovorin, irinotecan, and oxaliplatin to inhibit DNA synthesis and induce apoptosis in cancer cells. Used for Metastatic colorectal cancer (phase 3 investigation).

At a glance

Generic namemFOLFIRINOX-FOLFIRI intensified chemotherapy
SponsorSeoul National University Hospital
Drug classCombination chemotherapy regimen
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

This regimen represents an escalated dosing strategy of standard FOLFIRI (fluorouracil, leucovorin, irinotecan) with the addition of oxaliplatin from the FOLFOX backbone. The combination targets multiple pathways: fluorouracil inhibits thymidylate synthase and incorporates into DNA/RNA; irinotecan inhibits topoisomerase I; and oxaliplatin forms DNA cross-links. The intensified approach aims to improve efficacy in advanced colorectal cancer.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about mFOLFIRINOX-FOLFIRI intensified chemotherapy

What is mFOLFIRINOX-FOLFIRI intensified chemotherapy?

mFOLFIRINOX-FOLFIRI intensified chemotherapy is a Combination chemotherapy regimen drug developed by Seoul National University Hospital, indicated for Metastatic colorectal cancer (phase 3 investigation).

How does mFOLFIRINOX-FOLFIRI intensified chemotherapy work?

mFOLFIRINOX-FOLFIRI is an intensified chemotherapy regimen combining fluorouracil, leucovorin, irinotecan, and oxaliplatin to inhibit DNA synthesis and induce apoptosis in cancer cells.

What is mFOLFIRINOX-FOLFIRI intensified chemotherapy used for?

mFOLFIRINOX-FOLFIRI intensified chemotherapy is indicated for Metastatic colorectal cancer (phase 3 investigation).

Who makes mFOLFIRINOX-FOLFIRI intensified chemotherapy?

mFOLFIRINOX-FOLFIRI intensified chemotherapy is developed by Seoul National University Hospital (see full Seoul National University Hospital pipeline at /company/seoul-national-university-hospital).

What drug class is mFOLFIRINOX-FOLFIRI intensified chemotherapy in?

mFOLFIRINOX-FOLFIRI intensified chemotherapy belongs to the Combination chemotherapy regimen class. See all Combination chemotherapy regimen drugs at /class/combination-chemotherapy-regimen.

What development phase is mFOLFIRINOX-FOLFIRI intensified chemotherapy in?

mFOLFIRINOX-FOLFIRI intensified chemotherapy is in Phase 3.

What are the side effects of mFOLFIRINOX-FOLFIRI intensified chemotherapy?

Common side effects of mFOLFIRINOX-FOLFIRI intensified chemotherapy include Neutropenia, Diarrhea, Nausea/vomiting, Peripheral neuropathy, Anemia, Mucositis.

Related